AQR Capital Management
RXRX icon

AQR Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

AQR Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$750K Buy
+244,391
New +$944K ﹤0.01% 2916
2025
Q4 		– Sell
-14,910
Closed -$72.8K – 3633
2025
Q3 		$72.8K Buy
14,910
+1,010
+7% +$5.3K ﹤0.01% 3397
2025
Q2 		$70.3K Sell
13,900
-154,291
-92% -$758K ﹤0.01% 3220
2025
Q1 		$890K Buy
+168,191
New +$1.23M ﹤0.01% 2099
2024
Q2 		– Sell
-14,985
Closed -$149K – 2667
2024
Q1 		$149K Buy
+14,985
New +$167K ﹤0.01% 2300

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AQR Capital Management's RXRX Position: Q1 2026 in Review

AQR Capital Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 244,391 shares worth $750K. The stake represents ﹤0.01% of the portfolio and ranks #2916 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in RXRX as recently as Q3 2025.

AQR Capital Management first reported a position in RXRX in Q1 2024 and has held it in 5 quarters since. The position peaked at $890K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • AQR Capital Management held 244,391 shares of Recursion Pharmaceuticals worth $750K as of Q1 2026.
  • Recursion Pharmaceuticals was a new AQR Capital Management position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2916 holding.
  • AQR Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • AQR Capital Management's Recursion Pharmaceuticals position peaked at $890K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.